Fero Industries Comments On Recent FDA Advisory Panel Recommendation On Avandia(R)
Fero Industries Comments On Recent FDA Advisory Panel Recommendation On Avandia(R)
Fero Industries, Inc. (FROI - OTCBB) (the “Company”) is pleased to provide these comments regarding the recent Food and Drug Administration (”FDA”) advisory panel recommendation concerning the GlaxoSmithKline PLC (GSK:NYSE) diabetes drug Avandia®. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of …
Read more on Medical News Today
Related posts:
- HSA reviewing Avandia
- Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME
- Health ministry rules out any immediate action against controversial anti-diabetic drug rosiglitazone
- Connecticut’s Drug War is a Bust
- Amylin Pharmaceuticals to Present New Data and Insights From the Company’s Diabetes Programs at ADA 2010